GC-Rise’s mission is to improve women and children’s healthcare in China through innovation. The company has 2 lead drug products in the Chinese market; Remifemin as an alternative to HRT and Esberitox for immune support as well as a portfolio of synergistic products. GC-Rise offers a unique commercial platform to access family health in China.
A strategic partner
GC-Rise offers western partners unique access to this fast growing market by helping companies build a successful presence in China through policy interpretation, public affairs management, local registration, running of clinical trials, pricing, distribution to market promotion, brand-building and patient education. Through this GC-Rise provides novel and safe products for Chinese patients. The company has a number of follow-on products in the pipeline for launch in 2015+.
Recognition
The Company was listed in the top 50 fast-growing companies in China by Deloitte for two consecutive years and was the only pharmaceutical enterprise to be recognized.
www.gc-rise.com
Member count: 11-50
Total raised: $15M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Inventages | inventages... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 02.09.2014 | Series B | $15M | - | finsmes.co... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 02.09.2014 | GC-Rise Ph... | GC-Rise Pharmaceutical Co. Ltd... | China | - | finsmes.co... |
| 01.08.2012 | Women Heal... | BEIJING, July 31, 2012 /PRNews... | Venture Ca... | - | fiercebiot... |